Core Viewpoint - The F5 class action lawsuit alleges that F5, Inc. and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in light of a significant security incident that impacted its operations and stock price [1][4]. Company Overview - F5, Inc. is a global multi-cloud application security and delivery company that enables customers to deploy, secure, and operate applications both on-premises and via public cloud [3]. Allegations of the Lawsuit - The lawsuit claims that F5 created a false impression of having reliable information about its projected revenue and growth while downplaying risks associated with seasonality and macroeconomic factors [4]. - It is alleged that F5 was experiencing a significant security incident that jeopardized client security and the company's future prospects [4]. - On October 15, 2025, F5 disclosed a security breach involving a nation-state threat actor, leading to a nearly 14% drop in stock price over two trading days [5]. - Following the breach, F5 reported fourth quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026, resulting in an 11% decline in stock price over two trading days [6]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased F5 securities during the Class Period to seek appointment as lead plaintiff in the class action lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [8].

Kuwait's oil minister Tariq Al-Roumi told Reuters on Monday that he expects tenders for the Durra oil and gas field project, in cooperation with Saudi Arabia, to be launched this year. ...

For better or for worse, Mad Money's Jim Cramer cannot be accused of being politically partisan. Since admitting that he only cares about policies that help stocks make money in 2017, he has been consistently non- partisan about politicians and only critical about policies. In the case of President Trump, for example, Cramer has been supportive of measures like tax cuts and critical of tariffs. This is why Cramer took an unusual stance of defending President Trump on a recent Mad Money episode by exclaiming ...

Nvidia (NASDAQ:NVDA) just seems to keep the deals and partnerships coming. ...

Core Insights - Garrett Motion Inc. has introduced a breakthrough oil-free centrifugal compressor technology for HVAC systems, aiming to cover cooling demands from 7 to 500 Tons (25 to 1,750 kWc) [2][3] - The company plans to generate $1 billion in revenues outside its Turbo automotive business by 2030, leveraging proven automotive technologies for industrial HVAC applications [3] Technology and Innovation - The new HVAC compressor technology offers a superior alternative to existing solutions such as scroll, screw, and magnetic bearing-based compressors, utilizing efficient turbo machinery and high-speed electric motors [3] - The compressors are designed to enable significant energy savings of over 10% in real-life applications compared to current solutions [5] Sustainability and Cost Efficiency - Garrett's compressors support sustainability goals by facilitating the use of next-generation ultra-low GWP refrigerants and providing cost savings through lower energy consumption and reduced maintenance needs [4] - The compact and lightweight design allows for retrofitting onto existing installations, ensuring a fast payback for end users [4] Market Applications - The comprehensive portfolio of oil-free centrifugal compressors is tailored for various commercial HVAC needs, including rooftop units, chillers for comfort cooling, data center cooling, and battery energy storage applications [5] - Customer testing samples are currently available, with production set to begin in late 2026 [6]

Core Insights - Senseonics Holdings (SENS) shares increased by 5.3% to close at $7.33, supported by high trading volume, and have gained 26.1% over the past four weeks [1][2] Company Performance - The company achieved CE Mark approval for the Eversense 365 continuous glucose monitoring (CGM) system, which is the first one-year CGM and can integrate with compatible medical devices [2] - Senseonics is expected to report a quarterly loss of $0.43 per share, reflecting a year-over-year decline of 7.5%, while revenues are projected to be $14.2 million, representing a 71.1% increase from the previous year [3] Earnings Estimates - The consensus EPS estimate for Senseonics has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4]

PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncology, show that d ...

Core Viewpoint - Madrigal Pharmaceuticals, Inc. is set to release its fourth-quarter and full-year 2025 financial results on February 19, 2026, prior to the opening of U.S. financial markets [1] Company Overview - Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [3] - The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist aimed at addressing key underlying causes of MASH [3] - Rezdiffra is the first and only medication approved by both the FDA and European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3) [3] - An ongoing Phase 3 outcomes trial is currently evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [3]

Core Viewpoint - MindBio Therapeutics Corp. is advancing its AI-driven technology for drug and alcohol intoxication detection, aiming to disrupt traditional testing methods in the mining industry, particularly in South America [1][6]. Group 1: Technology and Applications - The company has developed a world-first AI prediction tool that analyzes voice to detect intoxication from substances like alcohol, hallucinogens, and plans to expand to other drugs [1][5]. - The technology is being positioned as an enterprise solution for the mining industry, where it can serve as a first-line screening method for multiple substances at entry points [2][3]. - Current drug and alcohol testing methods in the mining sector are slow, expensive, and invasive, often requiring bodily fluid samples, which the company's technology aims to replace with a non-invasive voice analysis [3][5]. Group 2: Market Opportunity and Industry Context - In Chile, over 75% of mining workers consume alcohol, with more than 40% identified as problem drinkers, and 9% using drugs, highlighting a significant market need for effective screening solutions [4]. - Internationally, 20-25% of occupational accidents are linked to substance use, indicating a substantial opportunity for MindBio's technology to reduce workplace incidents and associated costs [4]. - The CEO expressed optimism about the commercial interest from the mining industry, viewing it as a massive opportunity to transform drug and alcohol testing processes globally [6][7].

BUFFALO, N.Y.--(BUSINESS WIRE)---- $ROCK #ROCK--Gibraltar Industries, Inc. (Nasdaq: ROCK), a leading manufacturer and provider of products and services for the residential, agtech, and infrastructure markets, today announced that it has closed its acquisition of OmniMax International ("OmniMax") from funds managed by Strategic Value Partners, LLC and its affiliates following receipt of all required regulatory approvals and satisfaction of customary closing conditions. The all-cash transaction was valued at ...